Dr Nathaniel Milton leads the Amyloid Binding Peptides Research Group, who conduct academic research in the area of amyloid peptide interactions with proteins.
NeuroDelta Ltd carry out commercial research using established in silico screening techniques.
The Amyloid Binding Peptides Research Group
Amyloid fibrils are implicated in many disorders including Alzheimer's disease, Parkinson's disease, Type II Diabetes mellitus, Familial British Dementia, Familial Danish Dementia and Creutzfeldt-Jakob disease. The Amyloid Binding Peptides Research Group (Bachem PEPTalk 2013) has been led by Dr Nathaniel Milton since September 1996 and is relocating in October 2014 to the Faculty of Health and Social Sciences at Leeds Beckett University.
The Amyloid Binding Peptides Research Group has focused on the identification and characterization of endogenous amyloid-binding compounds. The binding of the Alzheimer's associated amyloid-ß peptide plus amylin and prion protein fragments to human catalase has been characterized by our group (Milton & Harris 2014) and the proposed catalase binding domain of a range of peptides suggested. The mechanisms for catalase neuroprotection against amyloid peptides, including amyloid-ß, amyloid-Bri, amyloid-Dan, amylin and prion protein fragments, have been characterized using an SH-SY5Y cell line overexpressing human catalase (Chilumuri et al 2013). The group has shown that the catalase-amyloid interaction inhibitor Benzothiazole aniline-tetra(ethylene glycol) and the catalase activity inhibitor 3-amino-1,2,4-triazole both block catalase neuroprotection leading to enhanced amyloid toxicity in catalase overexpressing neurons. These studies have confirmed that catalase neuroprotection against amyloid peptides involves both an activity dependent component and a catalase-amyloid binding interaction dependent component.
The group has also identified fibril formation conditions for the non-amyloidogenic rat amylin peptide (Milton & Harris 2013), which can be used to screen for novel amyloid-binding compounds. Using this screening we have identified a number of amyloid-binding compounds including the R9 peptide and Kissorphins. The Kissorphin binding to the Alzheimer's associated amyloid-ß peptide plus amylin and prion protein fragments has been characterized (Milton et al 2012) and models of KiSS-1 overexpression characterized (Chilumuri & Milton 2013).
Full details of the Amyloid-Binding Peptides Research Group's areas of research are included in the subsequent pages, which detail the discoveries related to Amyloid interactions with Catalase, Kisspeptin derived peptides including Kissorphin plus a Phosphorylated derivative of amyloid-ß and Cannabinoid neuroprotection against amyloid-ß. A full list of publications from the Amyloid-Binding Peptides Research Group are included in the Publications page.
© Copyright 2014. NeuroDelta Ltd. All Rights Reserved.